Increased asymmetric dimethylarginine (ADMA) levels and insulin resistance in non-diabetic stage I kidney disease

被引：0
|
作者：
Yilmaz, Mahmut Ilker
Caglar, Kayser
Sonmez, Alper
Cakir, Erdinc
Kaya, Ayper
Acikel, Cengizhan
Eyileten, Tayfun
Yenicesu, Mujdat
Oguz, Yusuf
Bilgi, Cumhur
Oktenli, Cagatay
Vural, Abdulgaffar
Zoccali, Carmine
机构：
[1] Gulhane Sch Med, Ankara, Turkey
[2] CNR, IBIM, Reggio Di Calabria, Italy
[3] Inst Biomed Clin Epidemiol & Pathophysiol Renal D, Reggio Di Calabria, Italy
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [41] Smoking is associated with increased plasma asymmetric dimethylarginine (ADMA) levels in patients with type 2 diabetes mellitus
    Fard, A
    Bryant, TA
    Tuck, CH
    Vest, JA
    Sciacca, R
    Di Tullio, MR
    Chen, NT
    Berglund, L
    Ginsberg, HN
    Homma, S
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 327A - 327A
  • [42] Asymmetric Dimethylarginine (ADMA) Regulation in Puromycin Aminonucleoside (PAN) Induced Chronic Kidney Disease (CKD)
    Cunningham, Mark W., Jr.
    Chen, Gin-Fu
    Tain, You-Lin
    Sasser, Jennifer
    Baylis, Chris
    FASEB JOURNAL, 2010, 24
  • [43] Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)
    Carmine Zoccali
    Francesca Mallamaci
    Giovanni Tripepi
    European Journal of Clinical Pharmacology, 2006, 62 : 131 - 135
  • [44] Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)
    Zoccali, C
    Mallamaci, F
    Tripepi, G
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (Suppl 1) : 131 - 135
  • [45] Chronic Kidney Disease in Non-Diabetic Older Adults: Associated Roles of the Metabolic Syndrome, Inflammation, and Insulin Resistance
    Zammit, Andrea R.
    Katz, Mindy J.
    Derby, Carol
    Bitzer, Markus
    Lipton, Richard B.
    PLOS ONE, 2015, 10 (10):
  • [46] Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease
    Emrich, Insa E.
    Zawada, Adam M.
    Martens-Lobenhoffer, Jens
    Fliser, Danilo
    Wagenpfeil, Stefan
    Heine, Gunnar H.
    Bode-Boeger, Stefanie M.
    CLINICAL RESEARCH IN CARDIOLOGY, 2018, 107 (03) : 201 - 213
  • [47] Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease
    Insa E. Emrich
    Adam M. Zawada
    Jens Martens-Lobenhoffer
    Danilo Fliser
    Stefan Wagenpfeil
    Gunnar H. Heine
    Stefanie M. Bode-Böger
    Clinical Research in Cardiology, 2018, 107 : 201 - 213
  • [48] Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?
    N. Chan
    J. Chan
    Diabetologia, 2002, 45 : 1609 - 1616
  • [49] Insulin resistance and insulin secretion in non-diabetic acromegalic patients
    Coculescu, M.
    Niculescu, D.
    Lichiardopol, R.
    Purice, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 (05) : 308 - 316
  • [50] Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death
    Hedblad, B
    Nilsson, P
    Engstrom, G
    Berglund, G
    Janzon, L
    DIABETIC MEDICINE, 2002, 19 (06) : 470 - 475
12345